51
|
Backner Y, Ben-Shalom I, Kuchling J, Siebert N, Scheel M, Ruprecht K, Brandt A, Paul F, Levin N. Cortical topological network changes following optic neuritis. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2020; 7:7/3/e687. [PMID: 32123044 PMCID: PMC7136064 DOI: 10.1212/nxi.0000000000000687] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 01/10/2020] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To differentiate between visual cortical network topology changes following optic neuritis (ON) stemming from different inflammatory disease types, we used mathematical graph theory-based tools to analyze functional imaging data. METHODS Sixty-two patients were recruited into this cross-sectional study, 23 of whom had neuromyelitis optica spectrum disorder (NMOSD) with ON, 18 with clinically isolated syndrome (CIS)-ON, and 21 with other CIS episodes. Twenty-six healthy controls (HCs) were also recruited. All participants underwent resting-state functional MRI. Visual networks were defined using 50 visual regions of interest. Analysis included graph theory metrics, including degree, density, modularity, and local and global efficiency. RESULTS Visual network density shows decreased connectivity in all patient groups compared with controls. A higher degree of connections is seen in both ON groups (CIS and NMOSD) compared with the the non-ON group. This pattern is most pronounced in dorsal-lateral regions. Information transfer efficiency and modularity were reduced in both CIS groups, but not in the NMOSD group, compared with the HC group. CONCLUSIONS Visual network density appears affected by the neurologic deficit sustained (ON), and connectivity changes are more evident in dorsal-lateral regions. Efficiency and modularity appear to be associated with the specific disease type (CIS vs NMOSD). Thus, topological cortical changes in the visual system are associated with the type of neurologic deficit within the limits set on them by the underlying pathophysiology. We suggest that cortical patterns of activity should be considered in the outcome of the patients despite the localized nature of ON.
Collapse
Affiliation(s)
- Yael Backner
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Ido Ben-Shalom
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Joseph Kuchling
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Nadja Siebert
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Michael Scheel
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Klemens Ruprecht
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Alexander Brandt
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Friedemann Paul
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine
| | - Netta Levin
- From the fMRI Unit (Y.B., I.B.-S., N.L.), Neurology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Experimental and Clinical Research Center (J.K., N.S., A.B., F.P.), Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Germany; NeuroCure Clinical Research Center (J.K., N.S., M.S., A.B., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Neurology (J.K., K.R., F.P.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; Department of Neuroradiology (M.S.), Charité-Universitätsmedizin Berlin, Germany; and Department of Neurology (A.B.), University of California, Irvine.
| |
Collapse
|
52
|
Posporis C, Beltran E, Dunning M, Espadas I, Gillespie S, Barry AT, Wessmann A. Prognostic Factors for Recovery of Vision in Canine Optic Neuritis of Unknown Etiology: 26 Dogs (2003-2018). Front Vet Sci 2019; 6:415. [PMID: 31824972 PMCID: PMC6882734 DOI: 10.3389/fvets.2019.00415] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Accepted: 11/07/2019] [Indexed: 12/03/2022] Open
Abstract
Optic neuritis (ON) is a recognized condition, yet factors influencing recovery of vision are currently unknown. The purpose of this study was to identify prognostic factors for recovery of vision in canine ON of unknown etiology. Clinical databases of three referral hospitals were searched for dogs with presumptive ON based on clinicopathologic, MRI/CT, and fundoscopic findings. Twenty-six dogs diagnosed with presumptive ON of unknown etiology, isolated (I-ON) and MUE-associated (MUE-ON), were included in the study. Their medical records were reviewed retrospectively, and the association of complete recovery of vision with signalment, clinicopathologic findings, and treatment was investigated. Datasets were tested for normality using the D'Agostino and Shapiro-Wilk tests. Individual datasets were compared using the Chi-squared test, Fisher's exact test, and the Mann-Whitney U-test. For multiple comparisons with parametric datasets, the one-way analysis of variance (ANOVA) was performed, and for non-parametric datasets, the Kruskal-Wallis test was performed to test for independence. For all data, averages are expressed as median with interquartile range and significance set at p < 0.05. Twenty-six dogs met the inclusion criteria. Median follow-up was 230 days (range 21–1901 days, mean 496 days). Six dogs (23%) achieved complete recovery and 20 dogs (77%) incomplete or no recovery of vision. The presence of a reactive pupillary light reflex (p = 0.013), the absence of fundoscopic lesions (p = 0.0006), a younger age (p = 0.038), and a lower cerebrospinal fluid (CSF) total nucleated cell count (TNCC) (p = 0.022) were statistically associated with complete recovery of vision. Dogs with I-ON were significantly younger (p = 0.046) and had lower CSF TNCC (p = 0.030) compared to the MUE-ON group. This study identified prognostic factors that may influence complete recovery of vision in dogs with ON. A larger cohort of dogs is required to determine whether these findings are robust and whether additional parameters aid accurate prognosis for recovery of vision in canine ON.
Collapse
Affiliation(s)
| | - Elsa Beltran
- Queen Mother Hospital for Animals, Royal Veterinary College, Hatfield, United Kingdom
| | - Mark Dunning
- School of Veterinary Medicine and Science, University of Nottingham, Loughborough, United Kingdom.,Willows Veterinary Centre and Referral Service, Shirley, United Kingdom
| | - Irene Espadas
- Neurology/Neurosurgery Service, Pride Veterinary Centre, Derby, United Kingdom.,Small Animal Teaching Hospital, School of Veterinary Sciences, University of Liverpool, Neston, United Kingdom
| | - Sabrina Gillespie
- Queen Mother Hospital for Animals, Royal Veterinary College, Hatfield, United Kingdom
| | - Amy Teresa Barry
- Queen Mother Hospital for Animals, Royal Veterinary College, Hatfield, United Kingdom
| | - Annette Wessmann
- Neurology/Neurosurgery Service, Pride Veterinary Centre, Derby, United Kingdom
| |
Collapse
|